Patient Selection for Eribulin in Breast Cancer

Research Updates in Myasthenia GravisПодробнее

How to select treatment for HER2+ breast cancer patients with brain metastasis?Подробнее

Eribulin in Metastatic Breast CancerПодробнее

Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant studyПодробнее

Treatment With Eribulin Mesylate in Metastatic Breast CancerПодробнее

Eribulin as Treatment for Metastatic Breast CancerПодробнее

Treatment With Eribulin in Metastatic Breast CancerПодробнее

Eribulin in Recurrent Metastatic ER+ Breast CancerПодробнее

Eribulin is effective in pretreated advanced breast cancer patientsПодробнее

Eribulin’s Role in Triple-Negative Breast CancerПодробнее

Atezolizumab, Cobimetinib, and Eribulin in Patients With Metastatic Inflammatory Breast CancerПодробнее

Dr. Twelves on a Pooled Analysis of Eribulin in Breast CancerПодробнее

Dr. Llombart-Cussac on Eribulin in HER2-Negative Metastatic Breast CancerПодробнее

Dual MOA for Eribulin in Breast CancerПодробнее

Recent data on eribulin in metastatic breast cancer patients from SABCSПодробнее

The importance of patient selection in breast cancer trialsПодробнее

A Study Investigating Pembrolizumab in Combination With Eribulin in TNBCПодробнее

Joyce O’Shaughnessy, MD: Main Indications for Dose Reduction With EribulinПодробнее

Preclinical Observations on Eribulin for Breast CancerПодробнее

HER2+ Breast Cancer: Neratinib Patient SelectionПодробнее